Language

English

Publication Date

3-1-2026

Journal

Atherosclerosis

DOI

10.1016/j.atherosclerosis.2026.120670

PMID

41687316

Abstract

Cardiovascular disease remains the leading cause of death worldwide with low density lipoprotein being a major, yet modifiable, risk factor. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a central role in regulating low density lipoprotein (LDL) receptor expression. Naturally occurring loss-of-function variants in the PCSK9 gene result in lifelong lower LDL cholesterol (LDL-C) levels and significantly lower risk of atherosclerotic cardiovascular disease (ASCVD), providing strong genetic validation of PCSK9 as a therapeutic target. This insight has driven the development of therapies directed at PCSK9 for the management of hypercholesterolaemia, particularly in patients who fail to meet LDL-C targets despite maximally tolerated statin and ezetimibe. This is especially the case for patients who are statin intolerant or who have homozygous or heterozygous familial hypercholesterolaemia. The field has progressed rapidly from monoclonal antibodies to small interfering RNA and oral therapies, with gene editing strategies offering a potentially permanent inhibition of PCSK9. This review summarizes the evidence supporting the currently approved PCSK9 inhibitors. We discuss some novel therapies that are currently in development and consider some expanding indications for PCSK9 inhibition.

Keywords

Humans, PCSK9 Inhibitors, Proprotein Convertase 9, Cholesterol, LDL, Anticholesteremic Agents, Serine Proteinase Inhibitors, Animals, Biomarkers, Antibodies, Monoclonal, Hypercholesterolemia, Atherosclerosis, Treatment Outcome, Hyperlipoproteinemia Type II, Cardiovascular Diseases, Atherosclerotic cardiovascular disease, Cardiovascular risk, LDL cholesterol, Lipid-lowering therapy, PCSK9

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.